rare frequency of gene variation and survival analysis in thymic epithelial tumors

Objective: Thymic epithelial tumor (TET) is a rare mediastinal neoplasm and little is known about its genetic variability and prognostic factors. This study investigated the genetic variability and prognostic factors of TET. Patients and methods: We sequenced 22 cancer-related hotspot genes in TET tissues and matched normal tissues using Ampliseq Ion Torrent next-generation technology. Overall survival was evaluated using Kaplan–Meier methods and compared with log-rank tests. Results: A histological analysis of 52 patients with a median age of 52 years showed 15 patients (28.8%) with thymic carcinoma, five with type A thymoma (9.6%), eight with type AB (15.4%), six with type B1 (11.5%), nine with type B2 (17.3%), and nine with type B3 thymoma (17.3%). Three gene mutations were identified, including two with PIK3CA mutation and one with EGFR mutation. The three patients with mutant genes included two cases of thymoma (one with EGFR and the other with PIK3CA mutation) in addition to a case of thymic carcinoma ( PIK3CA mutation). The 5-year survival rates were 77.7% in all patients. The 5-year survival rates were 93.3%, 90.0%, 76.9%, and 22.9% corresponding to Masaoka stages I, II, III, and IV ( P , 0.001). The 5-year survival rates were 100%, 100%, 83.3%, 88.9%, 65.6%, and 60.9% in the histological subtypes of A, AB, B1, B2, and B3 thymomas, and thymic carcinoma, respectively ( P = 0.012). Conclusion: Hotspot gene mutations are rare in TET. PIK3CA and EGFR mutations represent candidate driver genes and treatment targets in TET. Masaoka stage and histological subtypes predict the survival of TET.

[1]  Jian-Hua Fu,et al.  Management of thymic tumors-consensus based on the Chinese Alliance for Research in Thymomas Multi-institutional retrospective studies. , 2016, Journal of thoracic disease.

[2]  A. Marx,et al.  Clinicopathological analysis of 241 thymic epithelial tumors-experience in the Shanghai Chest Hospital from 1997-2004. , 2016, Journal of thoracic disease.

[3]  H. Asamura,et al.  Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese Nationwide Database Study. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[4]  Wenke Liu,et al.  Thymic carcinoma patients with myasthenia gravis exhibit better prognoses , 2016, International Journal of Clinical Oncology.

[5]  Jian-Hua Fu,et al.  Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database , 2016, Annals of Surgical Oncology.

[6]  P. Meltzer,et al.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. , 2015, The Lancet. Oncology.

[7]  M. Hellmich,et al.  PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies , 2014, Oncotarget.

[8]  H. Sasaki,et al.  Genetic profiling of thymic carcinoma using targeted next-generation sequencing. , 2014, Lung cancer.

[9]  Jaime Rodriguez-Canales,et al.  A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors , 2014, Nature Genetics.

[10]  G. Giaccone,et al.  Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. , 2014, The Lancet. Oncology.

[11]  P. Stephens,et al.  Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses , 2013, Oncotarget.

[12]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[13]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[15]  H. Sasaki,et al.  Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  A. Marx,et al.  Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience , 2010, British Journal of Cancer.

[17]  N. Girard,et al.  Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas , 2009, Clinical Cancer Research.

[18]  G. Rossi,et al.  Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  H. Ohmatsu,et al.  Mutational status of EGFR and KIT in thymoma and thymic carcinoma. , 2008, Lung cancer.

[20]  H. Sasaki,et al.  Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. , 2006, Japanese journal of clinical oncology.

[21]  W. Pao,et al.  Phase II study of gefitinib treatment in advanced thymic malignancies , 2005 .

[22]  A. Marx,et al.  Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. , 2004, The New England journal of medicine.

[23]  C. Pan,et al.  Expression of apoptosis‐related markers and HER‐2/neu in thymic epithelial tumours , 2003, Histopathology.

[24]  R. Pfeiffer,et al.  Malignant thymoma in the United States: Demographic patterns in incidence and associations with subsequent malignancies , 2003, International journal of cancer.

[25]  J. Welsh,et al.  Thymoma and multiple malignancies: a case of five synchronous neoplasms and literature review. , 2003, Clinical medicine & research.

[26]  A. Rosenwald,et al.  Recurrent genetic aberrations in thymoma and thymic carcinoma. , 2000, The American journal of pathology.

[27]  H. Asamura,et al.  A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non‐invasive thymoma , 1994, Pathology international.

[28]  Y. Tseng,et al.  Thymic neuroendocrine carcinoma and thymoma are both associated with increased risk of extrathymic malignancy: a 20-year review of a single institution. , 2011, The Annals of thoracic surgery.